Altium Capital Management is based out of New York. Their last reported 13F filing for Q1 2025 included $41,500,012 in managed 13F securities
and a top 10 holdings concentration of 86.71%. Altium Capital Management's largest holding is Zevra Therapeutics Inc with shares held of 1,287,333. Whalewisdom has at least 21 13F filings, and 175 13G filings

2025-03-31
Top Buys (13F)
Name | % Change |
---|---|
ALNY Alnylam Pharmaceutic (PUT) | 16.27% |
INBS Intelligent Bio Solu | 0.52% |
STSS Sharps Technology In | 0.27% |
LGMK LogicMark Inc | 0.26% |
SBFMD Sunshine Biopharma I | 0.23% |

2025-03-31
Top Sells (13F)
Name | % Change |
---|---|
ADMA ADMA Biologics Inc | 6.79% |
VERA Vera Therapeutics In | 5.18% |
SRPT Sarepta Therapeutics | 4.38% |
ESTA Establishment Labs H | 3.99% |
ESTA Establishment Labs H (CALL) | 3.92% |

2025-03-31
13F Holdings Summary
Name | $ Change |
---|---|
ZVRA Zevra Therapeutics I | 23.23% |
ALNY Alnylam Pharmaceutic(PUT) | 16.27% |
EOLS Evolus Inc | 8.59% |
XTNT XTANT MED HLDGS INC | 8.21% |
AVDL Avadel Pharmaceutica | 7.91% |

2025-03-31
13F Activity
Market Value | $41.5m, Prior: $353m |
Inflows (Outflows) as % of Total MV | (-127.6981)% |
New Purchases | 5 stocks |
Added To | 0 stocks |
Sold out of | 48 stocks |
Reduced holdings in | 18 stocks |
Top 10 Holdings % | 86.71% |
Turnover %[1] | 73.61% |
Turnover Alt %[2] | 17.54% |
Time Held Top 20 | 0.7 quarters |
Time Held Top 10 | 0.7 quarters |
Time Held All | 2.96 quarters |
[1]: Turnover is calculated by taking the # of new holdings (initial purchases) + the # of positions sold out of (not just reduced) divided by the total # of holdings for the quarter.
[2]: Alt Turnover is calculated by taking either the total MV of new purchases or the MV of securities sold, whichever is less, divided by the total MV of the fund.

2025-03-31
13F Sector Allocation Over Time
limited to past 4 quarters. Subscribe to see all available data

2025-03-31
Analysis

Top 20 equal-weighted holdings. Performance numbers calculated through 2025-03-31